Parkinson’s Promising Therapies

Introduction

Parkinson’s disease (PD), a neurological disorder, takes place due to the brain’s low capacity to generate required dopamine, showing symptoms such as slowness, plus non-motor problems, tremors, etc., that later lead to fatigue, depression and sleep issues. The treatment to control these issues is not yet designed in the healthcare sector, but physical therapy, lifestyle changes and medication are highly recommended by healthcare professionals, promoting a self-healing approach.

Hope

Parkinson’s disease has witnessed many efforts, such as fixing neuronal damage and introducing whole new therapeutic procedures and more. The Gain Therapeutics, AC Immune and Ventyx Therapeutics etc holds the potential to bring next-generation robust Parkinson’s disease treatment with their continuous initiatives and struggle in this space. Recently, Parkinson met one groundbreaking solution established by AC Immune that spotted steadiness of the disease in its relevant mid-stage trial.

Though the dollars invested in bags with millions for Parkinson’s disease research are still struggling at the surface. The professor of neurology at the University of Washington, Pinky Agarwal, wrote in an email, “There's a need to establish new drugs, a solution and discover different therapeutic approaches for the neurodegenerative condition.”

History of Parkinson’s disease treatments

The search for a valid and effective treatment for Parkinson’s started in the late 1960s, when the clinical advantages of synthetic levodopa were spotted just after scientists addressed dopamine depletion and positioned it as an asset to Parkinson’s. After finding its potential, the company placed the drug for testing for numerous combinations with existing drugs. These efforts were the first ever hope to cool down the side effects and enhance the efficacy rate. In 1975 decarboxylase inhibitor carbidopa worked best in combination with synthetic levodopa.

This was the beginning for new era and initiatives for many other treatment alternatives that involved merging the relevant and effective drugs that stimulate dopamine receptors in the brain. The solid examples describing the same are Boehringer Ingelheim’s Mirapex, whereas Supernus Pharmaceuticals’ Xadago inhibit enzymes that diminish dopamine.

Director of the Parkinson’s Disease and Movement Disorder Center at Johns Hopkins Medicine, Kelly Mills, wrote in an email, “These shortages are calling for a need for novel treatments for Parkinson’s, mainly those who practice precision medicine to the condition and focus on the fundamental biology”. He added, “I observed that the therapies may need to focus on ‘predominant mechanisms in individuals, ’for example, the trials executing immunosuppression or immunomodulation will be considered for blood/CSF-related biomarkers or imaging.”